Can the Pneumococcal Vaccine Cause Injury and/or Death?

Can the Pneumococcal Vaccine Cause Injury and/or Death?

Can the Pneumococcal Vaccine Cause Injury and/or Death?

IMPORTANT NOTE: Corvelva invites you to get in-depth information by reading all the sections and links, as well as the manufacturer's product leaflets and technical data sheets, and to speak with one or more trusted professionals before deciding to vaccinate yourself or your child. This information is for informational purposes only and is not intended as medical advice.

According to the US CDC, problems that can arise after vaccination with 13-valent pneumococcal conjugate vaccine (PCV13), 23-valent pneumococcal polysaccharide vaccine (PPSV23), and any other vaccines include:(1-2)

  • Serious allergic reactions occurring within minutes to hours of vaccination.
  • Severe shoulder pain limiting movement of the injected arm.
  • Fainting or collapsing after vaccination. You may be advised to sit or lie down for about 15 minutes after the vaccination to avoid fainting and injury that could result from a fall. It is important to inform your doctor if you experience ringing in the ears, vision changes or dizziness after vaccination.

Side Effects of PCV13 Vaccine (Pneumococcal Conjugate Vaccine)
Adverse reactions following administration of PCV13 vary according to the dose of the series and the age of the recipient. In children, the most commonly reported reactions were irritability, drowsiness, loss of appetite, redness, pain, or swelling at the vaccine site, and mild to moderate fever.
Children who received PCV13 at the same time as inactivated flu vaccine were found to be at increased risk of febrile seizures.
In adults, redness, swelling and pain at the injection site, fatigue, fever, chills, headache and body aches have mainly been reported.(3)

Prevenar 13 (PCV13) adverse reactions reported in infants and children during pre-approval clinical studies:(4) injection site pain, swelling, redness, fever, decreased appetite, increased and decreased sleep, irritability, diarrhoea, vomiting, rash, hives, hypersensitivity reaction including bronchospasm, swollen face and shortness of breath, seizures, pneumonia, gastroenteritis, bronchiolitis, death (reported as SIDS).

Prevenar 13 (PCV13) adverse reactions reported in adults during pre-approval clinical studies:(5) pain, swelling and redness at the injection site, restriction of arm movement, fever, vomiting, chills, muscle aches, fatigue, headache, decreased appetite, rash, joint pain, death (deaths reported in pre- approval included deaths from cancer, heart disease, peritonitis, Mycobacterium avium complex lung infection, and septic shock).

Prevenar 13 (PCV13) adverse reactions reported post-marketing:(6) Cyanosis, injection site lymphadenopathy, anaphylaxis, shock, hypotonia, pallor, apnea, angioneurotic oedema, erythema multiforme, injection site pruritus, urticaria, and rash.

Pre-approval clinical trials of the first pneumococcal conjugate vaccine, Prevenar (PCV7)compared the safety of Prevenar (PCV7) to an investigational meningitis C vaccine, seriously undermining the scientific validity of the trial.
In pre-authorisation clinical studies of Prevenar (PCV7), children in the groups receiving the pneumococcal vaccine suffered more from seizures, irritability, high fever and other reactions. There were 7 deaths in the Prevenar group (PCV12), including 5 deaths from sudden infant death syndrome (SIDS). No long-term studies have been completed to evaluate whether Prevenar vaccine (PCV7), given alone or in combination with other vaccines, has an association with chronic disease or disability, such as the development of diabetes, asthma, seizure disorder, difficulty of learning, ADHD.(7)

Pre-approval safety trials of Prevenar 13 (PCV13) compared this next-generation vaccine with the original Prevenar vaccine (PCV7), a vaccine inadequately studied for safety, and concerns were reported in 2012 about a link between febrile seizures and Prevenar 13 (PCV13).(8-9)

PCV13 was associated with an elevated risk of febrile seizures when administered independently(10) and when given in combination with parenterally inactivated influenza vaccine (IIV).(11) 

Some studies have also linked the PCV vaccine to Guillain-Barre syndrome,(12) to polyserositis,(13) to the septic shoulder(14) and erythema multiforme.(15)

Side effects of PPSV23 vaccine (Pneumococcus polysaccharide)
According to the CDC, about 50 percent of people who receive the pneumococcal polysaccharide vaccine (PPSV23) experience pain and redness at the injection site. Body aches, fever and more severe local reactions can also occur after administration of PPSV23.(16)

Adverse reactions of PNEUMOVAX23 (PPSV23) reported in adults during pre-approval US clinical trials:(17) injection site pain, redness, itching, bruising and swelling, headache, chills, fever, diarrhea, dyspepsia, nausea, upper respiratory tract infection, back pain, neck pain, pharyngitis, muscle pain, fatigue, depression, colitis ulcer, chest pain, angina pectoris, heart failure, tremor, rigors, sweating, stroke, lumbar radiculopathy, pancreatitis, myocardial infarction, death. 

Nearly 80% of subjects participating in the pre-approval clinical studies experienced an injection site adverse reaction following revaccination three to five years after the initial vaccine. The rate of systemic adverse reactions (headache, fatigue, myalgia) following revaccination with PPSV23 was also higher, with 33% of adults 65 years of age and older and 37,5% of adults aged 50 years and older. between 64 and XNUMX years who reported an adverse reaction.(18)

Adverse Reactions of PNEUMOVAX23 (PPSV23) Reported Post-Marketing:(19) Anaphylactoid reactions, serum sickness, angioneurotic oedema, arthritis, arthralgia, vomiting, nausea, decreased mobility of extremities, edema peripheral in injected limb, fever, malaise, cellulitis, injection site warmth, lymphadenopathy , lymphadenitis, leukocytosis, thrombocytopenia in patients with stable idiopathic thrombocytopenic purpura, haemolytic anemia in patients who have had other haematological disorders, paraesthesia, Guillain-Barré syndrome, radiculoneuropathy, febrile convulsions, rash, erythema multiforme, urticaria, cellulitis-like reactions. 

Although PNEUMOVAX23 (PPSV23) is approved for use in children two years of age and older with conditions such as chronic heart and lung disease, diabetes, cochlear implants, CSF leaks, sickle cell disease, functional or anatomical asplenia, and immunosuppression, no information on the safety or efficacy of the vaccine in children is available from the vaccine package insert.(20)

Some studies have linked PPSV23 to systemic inflammatory reactions(21) and fever.(22-23-24-25-26)

This article is summarized and translated by National Vaccine Information Center.

Corvelva

Publish the Menu module to "offcanvas" position. Here you can publish other modules as well.
Learn more.